InstalabLoading...
InstalabLoading...
An anti-inflammatory signaling protein that reveals how effectively your immune system is keeping its own responses in check.
When your immune system detects a threat, it launches an inflammatory response. But that response has to stop at some point, or it starts damaging your own tissues. IL-10 (interleukin-10) is one of the key molecules your body uses to apply the brakes. Measuring IL-10 in your blood gives you a window into how well your body is regulating inflammation, and whether it might be struggling to keep that regulation in balance.
What makes IL-10 unusual is that it does not simply tell you "more is better" or "less is better." In most situations, IL-10 acts as a protective, calming signal. But in certain autoimmune conditions, elevated IL-10 can actually fuel the problem. Understanding your IL-10 level means understanding context: what your body is responding to and whether the response is helping or hurting.
Nearly every type of immune cell can produce IL-10, from the large scavenger cells called macrophages to various types of T cells, B cells, and even non-immune cells like the cells lining your skin and gut. Once released, IL-10 locks onto a two-part receptor on the surface of immune cells and activates an internal signaling chain (called the JAK1/TYK2-STAT3 pathway) that tells those cells to dial down their inflammatory activity.
The primary targets of this calming signal are the innate immune cells that act as your body's first responders. IL-10 reduces their production of several major pro-inflammatory molecules, including IL-1, IL-6, IL-12, and TNF-alpha. It also makes these cells less effective at presenting pieces of invaders to other immune cells, which slows the cascade of immune activation.
At a deeper level, IL-10 actually changes how immune cells generate energy. In macrophages, it shifts the cell's metabolism away from the rapid-burn fuel system associated with inflammation and toward a more efficient, steady-state energy system. This metabolic shift triggers a cleanup process that removes damaged cellular power plants (mitochondria), further reducing inflammatory signals.
If IL-10 were purely anti-inflammatory, interpreting your result would be straightforward. But IL-10 has a second, less intuitive role: it can stimulate certain parts of the immune system. Specifically, it acts as a growth factor for B cells, the immune cells responsible for producing antibodies. It enhances their ability to present molecules on their surface and encourages them to produce certain classes of antibodies.
IL-10 can also boost the activity of cytotoxic T cells (the immune cells that kill virus-infected or cancerous cells) and natural killer cells. This means a high IL-10 level does not always mean your immune system is being suppressed. Depending on the context, it could mean parts of your immune response are actually being amplified.
This dual nature is what makes IL-10 so important to understand. In conditions driven by overactive inflammatory cells, IL-10 is generally protective. But in conditions driven by overactive antibody production, like lupus, IL-10 can make things worse. Your IL-10 level gains meaning only when paired with the clinical picture.
The clearest example of what happens when IL-10 is missing comes from the gut. People born with genetic mutations that eliminate IL-10 or its receptor develop severe intestinal inflammation early in life, a form of inflammatory bowel disease so aggressive it often requires a bone marrow transplant. Even more common genetic variations that merely reduce IL-10 signaling are associated with increased risk of inflammatory bowel disease, while variants that boost IL-10 expression appear protective.
If you have ulcerative colitis or Crohn's disease, your IL-10 level may reflect how well your body is counterbalancing intestinal inflammation. Some people with IBD even develop autoantibodies that neutralize their own IL-10, essentially creating an acquired version of the genetic deficiency. This is a relatively recent discovery that may explain why some people with IBD respond poorly to standard treatments.
In rheumatoid arthritis, the picture is more complicated. IL-10 is produced in inflamed joint tissue, and blocking it in lab experiments causes inflammatory molecules to increase two to threefold. So locally, IL-10 is clearly trying to restrain inflammation. But systemically, people with rheumatoid arthritis can show dramatically elevated IL-10 levels (up to 50-fold higher mRNA levels than healthy controls), and higher blood levels correlate with greater levels of disease-associated autoantibodies like rheumatoid factor and anti-CCP.
What this means for you: if you have rheumatoid arthritis, a high IL-10 level does not necessarily mean your inflammation is well controlled. It may instead reflect your body's increasingly desperate attempt to regulate a process that is outpacing its control mechanisms, or it may be contributing to autoantibody production.
In lupus, IL-10 plays a clearly harmful role. High IL-10 levels drive B cells to differentiate directly into antibody-producing cells outside the normal checkpoint process, flooding the system with autoantibodies. This is the opposite of what IL-10 does in the gut, and it illustrates why this biomarker cannot be interpreted without knowing what condition you are tracking.
IL-10 has also been proposed as a predictor of severity and outcomes in COVID-19 and post-COVID syndrome, reflecting its role as a barometer of how intensely the immune system is both attacking and trying to restrain itself during acute infection.
Because IL-10 is produced in response to immune activation, your level is primarily driven by the state of your immune system rather than by simple lifestyle inputs. That said, several interventions have been studied for their effects on IL-10 or IL-10-related pathways.
Targeted biologic therapies: In rheumatoid arthritis, engineered versions of IL-10 designed to travel more efficiently to lymph nodes (where immune decisions are made) have shown efficacy comparable to anti-TNF therapy in animal models. This approach reflects a shift toward delivering IL-10 to the right tissue rather than flooding the bloodstream with it. Clinical trials of systemic IL-10 injections in rheumatoid arthritis, psoriasis, type 1 diabetes, and multiple sclerosis have generally produced disappointing results, largely because IL-10 acts in highly localized, compartmentalized ways that systemic dosing fails to replicate.
Topical or localized delivery: In steroid-resistant ulcerative colitis, IL-10 delivered directly to the colon via enema dramatically reduced pro-inflammatory cytokine release both locally and throughout the body. This is consistent with the principle that IL-10's effects depend heavily on where it acts. In experimental models, IL-10 administration alleviates ulcerative colitis by promoting cellular cleanup processes (autophagy), reducing cell death in the gut lining, and lowering oxidative stress.
Screening for anti-IL-10 antibodies: If you have inflammatory bowel disease that is difficult to control, it may be worth discussing with your clinician whether neutralizing autoantibodies against IL-10 could be contributing to your disease. This is an emerging area, but the identification of these antibodies in some IBD patients suggests a subset of people whose disease is driven by acquired IL-10 deficiency.